Clinical Trials Browser

Completed × Has announcements × Gemcitabine × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04083235 2026-03-09

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 2 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 2 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 3 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 2 FDA

Breast

Breast Neoplasms

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3 Completed

572 enrolled 32 charts 3 FDA

Thoracic

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed

529 enrolled 23 charts 2 FDA

Breast

Breast Neoplasms

Clinical Trials

KEYNOTE-966

NAPOLI 3

innovaTV 301

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

CheckMate 816

CheckMate 227

KEYNOTE-355

TROPiCS-02

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

ASCENT